- Home
- UNCY vs CURR Comparison
UNCY vs CURR Comparison
Compare UNCY & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CURR
- Stock Information
- Founded
- UNCY 2016
- CURR 2013
- Country
- UNCY United States
- CURR Singapore
- Employees
- UNCY N/A
- CURR N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CURR Business Services
- Sector
- UNCY Health Care
- CURR Consumer Discretionary
- Exchange
- UNCY Nasdaq
- CURR Nasdaq
- Market Cap
- UNCY 91.0M
- CURR 74.0M
- IPO Year
- UNCY 2021
- CURR N/A
- Fundamental
- Price
- UNCY $4.55
- CURR $1.04
- Analyst Decision
- UNCY Strong Buy
- CURR Strong Buy
- Analyst Count
- UNCY 4
- CURR 1
- Target Price
- UNCY $63.75
- CURR $3.50
- AVG Volume (30 Days)
- UNCY 1.5M
- CURR 8.6M
- Earning Date
- UNCY 08-13-2025
- CURR 08-11-2025
- Dividend Yield
- UNCY N/A
- CURR N/A
- EPS Growth
- UNCY N/A
- CURR N/A
- EPS
- UNCY N/A
- CURR N/A
- Revenue
- UNCY N/A
- CURR $43,386,858.00
- Revenue This Year
- UNCY N/A
- CURR N/A
- Revenue Next Year
- UNCY $1,458.53
- CURR $21.53
- P/E Ratio
- UNCY N/A
- CURR N/A
- Revenue Growth
- UNCY N/A
- CURR N/A
- 52 Week Low
- UNCY $2.02
- CURR $0.33
- 52 Week High
- UNCY $11.00
- CURR $7.08
- Technical
- Relative Strength Index (RSI)
- UNCY 39.53
- CURR N/A
- Support Level
- UNCY $4.76
- CURR N/A
- Resistance Level
- UNCY $7.15
- CURR N/A
- Average True Range (ATR)
- UNCY 0.97
- CURR 0.00
- MACD
- UNCY -0.28
- CURR 0.00
- Stochastic Oscillator
- UNCY 7.37
- CURR 0.00
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.